1. Int J Cancer. 2021 Apr 15;148(8):1895-1909. doi: 10.1002/ijc.33457. Epub 2021 
Jan 9.

Gene- and pathway-level analyses of iCOGS variants highlight novel signaling 
pathways underlying familial breast cancer susceptibility.

Lonjou C(1)(2)(3), Eon-Marchais S(1)(2)(3), Truong T(4)(5), Dondon MG(1)(2)(3), 
Karimi M(4)(5), Jiao Y(1)(2)(3), Damiola F(6), Barjhoux L(6), Le Gal D(1)(2)(3), 
Beauvallet J(1)(2)(3), Mebirouk N(1)(2)(3), Cavaciuti E(1)(2)(3), Chiesa J(7), 
Floquet A(8), Audebert-Bellanger S(9), Giraud S(10), Frebourg T(11), Limacher 
JM(12), Gladieff L(13), Mortemousque I(14), Dreyfus H(15)(16), Lejeune-Dumoulin 
S(17), Lasset C(18)(19)(20), Venat-Bouvet L(21), Bignon YJ(22), Pujol P(23)(24), 
Maugard CM(25)(26), Luporsi E(27), Bonadona V(18)(19)(20), Noguès C(28)(29), 
Berthet P(30), Delnatte C(31), Gesta P(32), Lortholary A(33), Faivre L(34)(35), 
Buecher B(36), Caron O(37), Gauthier-Villars M(36), Coupier I(23)(24), Mazoyer 
S(38), Monraz LC(1)(2)(3), Kondratova M(1)(2)(3), Kuperstein I(1)(2)(3), Guénel 
P(4)(5), Barillot E(1)(2)(3), Stoppa-Lyonnet D(36)(39), Andrieu N(1)(2)(3), 
Lesueur F(1)(2)(3).

Author information:
(1)Inserm, U900, Institut Curie, Paris, France.
(2)Mines ParisTech, Fontainebleau, France.
(3)PSL Research University, Paris, France.
(4)Université Paris-Saclay, UVSQ, Inserm, CESP, Villejuif, France.
(5)Inserm U1018, CESP, Team Exposome and Heredity, Villejuif, France.
(6)Department of BioPathology, Centre Léon Bérard, Lyon, France.
(7)CHRU Hôpital Caremeau, Nîmes, France.
(8)Institut Bergonié, Bordeaux, France.
(9)Département de Génétique Médicale et Biologie de la Reproduction, CHU Brest, 
Hôpital Morvan, Brest, France.
(10)Service de Génétique, Hospices Civils de Lyon, Groupement Hospitalier Est, 
Bron, France.
(11)Département de Génétique, Hôpital Universitaire de Rouen, Rouen, France.
(12)Service d'Onco-Hématologie, Hôpital Pasteur, Colmar, France.
(13)Service d'Oncologie Médicale, Institut Claudius Regaud-IUCT-Oncopole, 
Toulouse, France.
(14)Service de Génétique, Hôpital Bretonneau, Tours, France.
(15)Clinique Sainte Catherine, Avignon, France.
(16)Département de Génétique, CHU de Grenoble, Hôpital Couple-Enfant, Grenoble, 
France.
(17)Service de Génétique Clinique Guy Fontaine, CHU Lille, Lille, France.
(18)Université Claude Bernard Lyon 1, Villeurbanne, France.
(19)CNRS UMR 5558, Lyon, France.
(20)Centre Léon Bérard, Unité de Prévention et Epidémiologie Génétique, Lyon, 
France.
(21)Service d'Oncologie Médicale, Hôpital Universitaire Dupuytren, Limoges, 
France.
(22)Département d'Oncogénétique, Université Clermont Auvergne, UMR INSERM, 
U1240, Centre Jean Perrin, Clermont Ferrand, France.
(23)Hôpital Arnaud de Villeneuve, CHU Montpellier, Service de Génétique Médicale 
et Oncogénétique, Montpellier, France.
(24)INSERM 896, CRCM Val d'Aurelle, Montpellier, France.
(25)Département d'Oncobiologie, LBBM, Hôpitaux Universitaires de Strasbourg, 
Génétique Oncologique Moléculaire, UF1422, Strasbourg, France.
(26)Hôpitaux Universitaires de Strasbourg, UF6948 Génétique Oncologique 
Clinique, Évaluation Familiale et Suivi, Strasbourg, France.
(27)ICL Alexis Vautrin, Unité d'Oncogénétique, Vandœuvre-lès-Nancy, France.
(28)Département d'Anticipation et de Suivi des Cancers, Oncogénétique Clinique, 
Institut Paoli-Calmettes, Marseille, France.
(29)Aix Marseille University, INSERM, IRD, SESSTIM, Marseille, France.
(30)Département de Biopathologie, Centre François Baclesse, Oncogénétique, Caen, 
France.
(31)Institut de Cancérologie de l'Ouest, Unité d'Oncogénétique, Saint Herblain, 
France.
(32)CH Georges Renon, Service d'Oncogénétique Régional Poitou-Charentes, Niort, 
France.
(33)Centre Catherine de Sienne, Service d'Oncologie Médicale, Nantes, France.
(34)Institut GIMI, CHU de Dijon, Hôpital d'Enfants, Dijon, France.
(35)Oncogénétique, Centre de Lutte contre le Cancer Georges François Leclerc, 
Dijon, France.
(36)Institut Curie, Service de Génétique, Paris, France.
(37)Département de Médecine Oncologique, Gustave Roussy, Villejuif, France.
(38)Equipe GENDEV, Centre de Recherche en Neurosciences de Lyon, Inserm U1028, 
CNRS UMR5292, Université Lyon 1, Université St Etienne, Lyon, France.
(39)Inserm, U830, Université Paris-Descartes, Paris, France.

Single-nucleotide polymorphisms (SNPs) in over 180 loci have been associated 
with breast cancer (BC) through genome-wide association studies involving mostly 
unselected population-based case-control series. Some of them modify BC risk of 
women carrying a BRCA1 or BRCA2 (BRCA1/2) mutation and may also explain BC risk 
variability in BC-prone families with no BRCA1/2 mutation. Here, we assessed the 
contribution of SNPs of the iCOGS array in GENESIS consisting of BC cases with 
no BRCA1/2 mutation and a sister with BC, and population controls. Genotyping 
data were available for 1281 index cases, 731 sisters with BC, 457 unaffected 
sisters and 1272 controls. In addition to the standard SNP-level analysis using 
index cases and controls, we performed pedigree-based association tests to 
capture transmission information in the sibships. We also performed gene- and 
pathway-level analyses to maximize the power to detect associations with 
lower-frequency SNPs or those with modest effect sizes. While SNP-level analyses 
identified 18 loci, gene-level analyses identified 112 genes. Furthermore, 31 
Kyoto Encyclopedia of Genes and Genomes and 7 Atlas of Cancer Signaling Network 
pathways were highlighted (false discovery rate of 5%). Using results from the 
"index case-control" analysis, we built pathway-derived polygenic risk scores 
(PRS) and assessed their performance in the population-based CECILE study and in 
a data set composed of GENESIS-affected sisters and CECILE controls. Although 
these PRS had poor predictive value in the general population, they performed 
better than a PRS built using our SNP-level findings, and we found that the 
joint effect of family history and PRS needs to be considered in risk prediction 
models.

© 2020 The Authors. International Journal of Cancer published by John Wiley & 
Sons Ltd on behalf of UICC.

DOI: 10.1002/ijc.33457
PMCID: PMC9290690
PMID: 33368296 [Indexed for MEDLINE]

Conflict of interest statement: Dr P. Pujol is a consultant for AstraZeneca, 
Pfizer, Roche, MSD, Exact Sciences, Abbvie, OncoDNA, Takeda and Novartis. He 
received research funding from AstraZeneca, Pfizer and Novartis. The other 
authors declare no conflict of interest.